Resveratrol improves motor function in patients with muscular dystrophies: an open-label, single-arm, phase IIa study
Abstract Muscular dystrophies (MDs) are inherited disorders characterized by progressive muscle weakness. Previously, we have shown that resveratrol (3,5,4′-trihydroxy-trans-stilbene), an antioxidant and an activator of the protein deacetylase SIRT1, decreases muscular and cardiac oxidative damage a...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/bf548d12dece47e28717140c32a296ef |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:bf548d12dece47e28717140c32a296ef |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:bf548d12dece47e28717140c32a296ef2021-12-02T12:33:53ZResveratrol improves motor function in patients with muscular dystrophies: an open-label, single-arm, phase IIa study10.1038/s41598-020-77197-62045-2322https://doaj.org/article/bf548d12dece47e28717140c32a296ef2020-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-77197-6https://doaj.org/toc/2045-2322Abstract Muscular dystrophies (MDs) are inherited disorders characterized by progressive muscle weakness. Previously, we have shown that resveratrol (3,5,4′-trihydroxy-trans-stilbene), an antioxidant and an activator of the protein deacetylase SIRT1, decreases muscular and cardiac oxidative damage and improves pathophysiological conditions in animal MD models. To determine whether resveratrol provides therapeutic benefits to patients with MDs, an open-label, single-arm, phase IIa trial of resveratrol was conducted in 11 patients with Duchenne, Becker or Fukuyama MD. The daily dose of resveratrol was 500 mg/day, which was increased every 8 weeks to 1000 and then 1500 mg/day. Primary outcomes were motor function, evaluated by a motor function measure (MFM) scale, muscular strength, monitored with quantitative muscle testing (QMT), and serum creatine kinase (CK) levels. Adverse effects and tolerability were evaluated as secondary outcomes. Despite the advanced medical conditions of the patients, the mean MFM scores increased significantly from 34.6 to 38.4 after 24 weeks of medication. A twofold increase was found in the mean QMT scores of scapula elevation and shoulder abduction. Mean CK levels decreased considerably by 34%. Diarrhoea and abdominal pain was noted in six and three patients, respectively. Resveratrol may provide some benefit to MD patients.Kentaro KawamuraShinobu FukumuraKoki NikaidoNobutada TachiNaoki KozukaTsugumi SeinoKingya HatakeyamaMitsuru MoriYoichi M. ItoAkiyoshi TakamiShiro HinotsuAtsushi KunoYukihiko KawasakiYoshiyuki HorioHiroyuki TsutsumiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-11 (2020) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Kentaro Kawamura Shinobu Fukumura Koki Nikaido Nobutada Tachi Naoki Kozuka Tsugumi Seino Kingya Hatakeyama Mitsuru Mori Yoichi M. Ito Akiyoshi Takami Shiro Hinotsu Atsushi Kuno Yukihiko Kawasaki Yoshiyuki Horio Hiroyuki Tsutsumi Resveratrol improves motor function in patients with muscular dystrophies: an open-label, single-arm, phase IIa study |
| description |
Abstract Muscular dystrophies (MDs) are inherited disorders characterized by progressive muscle weakness. Previously, we have shown that resveratrol (3,5,4′-trihydroxy-trans-stilbene), an antioxidant and an activator of the protein deacetylase SIRT1, decreases muscular and cardiac oxidative damage and improves pathophysiological conditions in animal MD models. To determine whether resveratrol provides therapeutic benefits to patients with MDs, an open-label, single-arm, phase IIa trial of resveratrol was conducted in 11 patients with Duchenne, Becker or Fukuyama MD. The daily dose of resveratrol was 500 mg/day, which was increased every 8 weeks to 1000 and then 1500 mg/day. Primary outcomes were motor function, evaluated by a motor function measure (MFM) scale, muscular strength, monitored with quantitative muscle testing (QMT), and serum creatine kinase (CK) levels. Adverse effects and tolerability were evaluated as secondary outcomes. Despite the advanced medical conditions of the patients, the mean MFM scores increased significantly from 34.6 to 38.4 after 24 weeks of medication. A twofold increase was found in the mean QMT scores of scapula elevation and shoulder abduction. Mean CK levels decreased considerably by 34%. Diarrhoea and abdominal pain was noted in six and three patients, respectively. Resveratrol may provide some benefit to MD patients. |
| format |
article |
| author |
Kentaro Kawamura Shinobu Fukumura Koki Nikaido Nobutada Tachi Naoki Kozuka Tsugumi Seino Kingya Hatakeyama Mitsuru Mori Yoichi M. Ito Akiyoshi Takami Shiro Hinotsu Atsushi Kuno Yukihiko Kawasaki Yoshiyuki Horio Hiroyuki Tsutsumi |
| author_facet |
Kentaro Kawamura Shinobu Fukumura Koki Nikaido Nobutada Tachi Naoki Kozuka Tsugumi Seino Kingya Hatakeyama Mitsuru Mori Yoichi M. Ito Akiyoshi Takami Shiro Hinotsu Atsushi Kuno Yukihiko Kawasaki Yoshiyuki Horio Hiroyuki Tsutsumi |
| author_sort |
Kentaro Kawamura |
| title |
Resveratrol improves motor function in patients with muscular dystrophies: an open-label, single-arm, phase IIa study |
| title_short |
Resveratrol improves motor function in patients with muscular dystrophies: an open-label, single-arm, phase IIa study |
| title_full |
Resveratrol improves motor function in patients with muscular dystrophies: an open-label, single-arm, phase IIa study |
| title_fullStr |
Resveratrol improves motor function in patients with muscular dystrophies: an open-label, single-arm, phase IIa study |
| title_full_unstemmed |
Resveratrol improves motor function in patients with muscular dystrophies: an open-label, single-arm, phase IIa study |
| title_sort |
resveratrol improves motor function in patients with muscular dystrophies: an open-label, single-arm, phase iia study |
| publisher |
Nature Portfolio |
| publishDate |
2020 |
| url |
https://doaj.org/article/bf548d12dece47e28717140c32a296ef |
| work_keys_str_mv |
AT kentarokawamura resveratrolimprovesmotorfunctioninpatientswithmusculardystrophiesanopenlabelsinglearmphaseiiastudy AT shinobufukumura resveratrolimprovesmotorfunctioninpatientswithmusculardystrophiesanopenlabelsinglearmphaseiiastudy AT kokinikaido resveratrolimprovesmotorfunctioninpatientswithmusculardystrophiesanopenlabelsinglearmphaseiiastudy AT nobutadatachi resveratrolimprovesmotorfunctioninpatientswithmusculardystrophiesanopenlabelsinglearmphaseiiastudy AT naokikozuka resveratrolimprovesmotorfunctioninpatientswithmusculardystrophiesanopenlabelsinglearmphaseiiastudy AT tsugumiseino resveratrolimprovesmotorfunctioninpatientswithmusculardystrophiesanopenlabelsinglearmphaseiiastudy AT kingyahatakeyama resveratrolimprovesmotorfunctioninpatientswithmusculardystrophiesanopenlabelsinglearmphaseiiastudy AT mitsurumori resveratrolimprovesmotorfunctioninpatientswithmusculardystrophiesanopenlabelsinglearmphaseiiastudy AT yoichimito resveratrolimprovesmotorfunctioninpatientswithmusculardystrophiesanopenlabelsinglearmphaseiiastudy AT akiyoshitakami resveratrolimprovesmotorfunctioninpatientswithmusculardystrophiesanopenlabelsinglearmphaseiiastudy AT shirohinotsu resveratrolimprovesmotorfunctioninpatientswithmusculardystrophiesanopenlabelsinglearmphaseiiastudy AT atsushikuno resveratrolimprovesmotorfunctioninpatientswithmusculardystrophiesanopenlabelsinglearmphaseiiastudy AT yukihikokawasaki resveratrolimprovesmotorfunctioninpatientswithmusculardystrophiesanopenlabelsinglearmphaseiiastudy AT yoshiyukihorio resveratrolimprovesmotorfunctioninpatientswithmusculardystrophiesanopenlabelsinglearmphaseiiastudy AT hiroyukitsutsumi resveratrolimprovesmotorfunctioninpatientswithmusculardystrophiesanopenlabelsinglearmphaseiiastudy |
| _version_ |
1718393882608140288 |